Apterna’s disease-area strategy begins where the unmet need is sharpest and the clinical impact could be most immediate: patients whose liver reserve is too poor to access potentially curative surgery. This gives the programme a tightly defined first setting in which functional liver recovery could change what becomes possible for patients.
From that focused starting point, the same therapeutic logic is intended to extend across the wider liver disease continuum. In the business plan, this means a staged expansion from surgical unlock into cirrhosis and transplant avoidance, and over time into the much larger fatty liver and obesity-related liver market. This approach allows Apterna to begin with a clear proof-of-concept pathway while building relevance across a substantially broader long-term opportunity.